However, it has been proposed that there is no association between EGFR expression and the poor outcome in colorectal cancer.[15–17] Here, we have examined VEGF and EGFR expression in plasma and tumor homogenates of mammary adenocarcinomas in order to evaluate the effect of goserelin administration, the potent LHRH agonist, “in vivo”. This evidence concerns the gene EGFR and neoplasm.